 "Pharma index hits record high as govt launches phase 3 of Covid vaccination")
Shares of pharmaceutical companies are in demand at the bourses with Nifty Pharma and the S&P BSE Healthcare indices gaining 2 per cent each and hitting their respective all-time highs on Tuesday as a significant resurge in Covid-19 cases across India led to spike in demand for Covid-related drugs.
Individually, Cipla, Gland Pharma, JB Chemicals and Pharmaceuticals, Max Healthcare, Neuland Laboratories and Apollo Hospital Enterprises hit their respective record highs today. Menawhile, Sun Pharmaceutical Industries, Cadila Healthcare, Glenmark Pharmaceuticals, Panacea Biotech and RPG Lifesicenes are among those that hit 52-week highs in the intra-day trade today.
Investors rushed to buy pharma stocks as the Indian government will open up vaccination to anyone over 18 years of age starting May 1 with greater flexibility on pricing, procurement and administration of vaccines. This opens up the private market for vaccination and provides more leeway to states and private companies.
"Better realisation in the private market along with reports of funding from the government for capacity expansion (Rs 3,000 crore/Rs 1,500 crore credit line for Serum Institute/Bharat Biotech) could have potential to spur vaccine production at a time when demand may spike with this eligibility relaxation," analysts at CLSA said in healthcare sector outlook report dated April 20.
For those at Axis Capital, the sudden spurt in Covid-related drugs will benefit players like Cipla, Dr Reddy’s, and Cadila who are scaling up capacity and production to meet the sudden rise in demand.
"The government measures to control the spread include approval of vaccines (which are still under trials) for emergency use – earlier Covaxin and now Sputnik-V by DRL/RDIF; ZyCovd by Cadila (in phase 3) expected by May. However, government procurement (at USD 2 per dose) and distribution is making it unviable for players to scale up production, given high costs/ investments in facilities, transportation and storage," the brokerage firm said. However, it expects 8-10 per cent growth for Indian Pharma Market (IPM) in FY22 (on lower FY21 base), but if Covid situation persists we could see a muted trend – similar to FY21.
At 01:50 pm, the S&P BSE Healthcare index (up 2 per cent at 23,570) and Nifty Pharma index (2 per cent at 13,522) were outperforming the benchmark indices, S&P BSE Sensex and Nifty50, which were up 0.16 per cent each. RPG Lifesciences, Vivimed Labs, Morepen Laboratories, Nectar Lifesciences, Wockhardt and Panacea Biotech were up in the range of 10 per cent to 20 per cent.
Individually, Cipla, Gland Pharma, JB Chemicals and Pharmaceuticals, Max Healthcare, Neuland Laboratories and Apollo Hospital Enterprises hit their respective record highs today. Menawhile, Sun Pharmaceutical Industries, Cadila Healthcare, Glenmark Pharmaceuticals, Panacea Biotech and RPG Lifesicenes are among those that hit 52-week highs in the intra-day trade today.
Investors rushed to buy pharma stocks as the Indian government will open up vaccination to anyone over 18 years of age starting May 1 with greater flexibility on pricing, procurement and administration of vaccines. This opens up the private market for vaccination and provides more leeway to states and private companies.
"Better realisation in the private market along with reports of funding from the government for capacity expansion (Rs 3,000 crore/Rs 1,500 crore credit line for Serum Institute/Bharat Biotech) could have potential to spur vaccine production at a time when demand may spike with this eligibility relaxation," analysts at CLSA said in healthcare sector outlook report dated April 20.
For those at Axis Capital, the sudden spurt in Covid-related drugs will benefit players like Cipla, Dr Reddy’s, and Cadila who are scaling up capacity and production to meet the sudden rise in demand.
"The government measures to control the spread include approval of vaccines (which are still under trials) for emergency use – earlier Covaxin and now Sputnik-V by DRL/RDIF; ZyCovd by Cadila (in phase 3) expected by May. However, government procurement (at USD 2 per dose) and distribution is making it unviable for players to scale up production, given high costs/ investments in facilities, transportation and storage," the brokerage firm said. However, it expects 8-10 per cent growth for Indian Pharma Market (IPM) in FY22 (on lower FY21 base), but if Covid situation persists we could see a muted trend – similar to FY21.
At 01:50 pm, the S&P BSE Healthcare index (up 2 per cent at 23,570) and Nifty Pharma index (2 per cent at 13,522) were outperforming the benchmark indices, S&P BSE Sensex and Nifty50, which were up 0.16 per cent each. RPG Lifesciences, Vivimed Labs, Morepen Laboratories, Nectar Lifesciences, Wockhardt and Panacea Biotech were up in the range of 10 per cent to 20 per cent.
Vivimed Labs was locked in the 20 per cent upper circuit band at Rs 28.40, having soared 66 per cent in the past three days, after the company announced that it has received approvals for 3 products from its manufacturing site in Hyderabad, which is PICS & Health Canada approved site. The company has received approval for Bilastine tablets 20mg under brand name ‘FLUSTIN’, Ornidazole and Otloxacin tablets under brand name ‘ORZOLE COMBI’ and Paracetamol 125mg/5ml and Chlorpheniramine Maleate Syrup 2mg/5ml 100ml under brand name ‘FEBRIL’.
| COMPANY | LATEST | PREV CLOSE | GAIN(%) |
| RPG LifeScience. | 479.10 | 399.25 | 20.0 |
| Morepen Labs. | 44.00 | 37.20 | 18.3 |
| Wockhardt | 521.05 | 457.30 | 13.9 |
| Panacea Biotec | 294.30 | 267.55 | 10.0 |
| Bliss GVS Pharma | 101.80 | 92.55 | 10.0 |
| Marksans Pharma | 58.10 | 53.40 | 8.8 |
| Dishman Carbogen | 143.35 | 132.50 | 8.2 |
| Astrazeneca Phar | 3,884.45 | 3,590.75 | 8.2 |
| Take Solutions | 49.10 | 45.40 | 8.2 |
| Suven Life Scie. | 91.70 | 84.90 | 8.0 |
| Shilpa Medicare | 408.00 | 377.95 | 8.0 |
| Gufic BioScience | 124.60 | 115.45 | 7.9 |
| Indrapr.Medical | 58.25 | 54.55 | 6.8 |
| IOL Chemicals | 601.90 | 564.50 | 6.6 |
| Fortis Health. | 213.55 | 200.50 | 6.5 |
| SPARC | 169.35 | 159.70 | 6.0 |
| Pfizer | 5,598.85 | 5,328.30 | 5.1 |
| Cadila Health. | 553.00 | 527.30 | 4.9 |
| Dr Reddy's Labs | 5,195.30 | 4,970.55 | 4.5 |
| Fermenta Biotec. | 314.05 | 301.60 | 4.1 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%